Compagnie Lombard Odier S Cm A Ascendis Pharma A/S Transaction History
Compagnie Lombard Odier S Cm A
- $7.2 Billion
- Q2 2025
A detailed history of Compagnie Lombard Odier S Cm A transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Compagnie Lombard Odier S Cm A holds 224 shares of ASND stock, worth $37,513. This represents 0.0% of its overall portfolio holdings.
Number of Shares
224Holding current value
$37,513% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ASND
# of Institutions
272Shares Held
61.7MCall Options Held
151KPut Options Held
226K-
Ra Capital Management, L.P. Boston, MA10.3MShares$1.72 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$918 Million4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$874 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$751 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$713 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $9.35B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...